Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program

Significant milestones are approaching in drug development; additional digital asset purchases expectedPreparation for FDA IND application ...
Morningstar

Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate

Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced clearance by the U.S. Food and Drug Administration (FDA) of ...
Medscape

Novel Drug With New Mechanism Promising for Parkinson’s Motor Fluctuations

Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...
Fierce Biotech

Panacea potential: How Nobel-winning regulatory T cells could become a 'universal drug'

In 2015, Bluestone led a small clinical trial to isolate and grow Tregs from diabetes patients and then reinfuse the cells ...

Sironax Announces Key Leadership Appointments to Advance Global Drug Discovery and Development

Senior Vice President of Preclinical Development Gary Ingenito, MD, Ph.D.: Senior Vice President of Clinical Development ...
GlobalData on MSN

FDA lifts clinical hold on Neurizon’s ALS drug

The lifting of the FDA’s clinical hold on Neurizon’s drug will pave the way for its investigation in the HEALEY-ALS trial.
Managed Healthcare Executive

FDA Accepts NDA for Investigational Maintenance Asthma Treatment

The FDA has accepted for review Chiesi’s New Drug Application (NDA) for their investigational maintenance treatment for ...